VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics Revenue

VistaGen Therapeutics had revenue of $1.04M in the twelve months ending December 31, 2023, down -386.42% year-over-year. Revenue in the quarter ending December 31, 2023 was $411.40K with 129.06% year-over-year growth. In the fiscal year ending March 31, 2023, VistaGen Therapeutics had annual revenue of $-227.30K, a decrease of -120.50%.

• Revenue (ttm): $1.04M
• Revenue Growth: -386.42%
• P/S Ratio: 123.16
• Revenue / Employee: $28,170
• Employees: 37
• Market Cap: 128.37M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2023	-227.30K	-1.34M	-120.50%
Mar 31, 2022	1.11M	19.40K	1.78%
Mar 31, 2021	1.09M	-	-
Mar 31, 2020	0	-	-
Mar 31, 2019	0	-	-
Mar 31, 2018	0	-	-
Mar 31, 2017	1.25M	-	-
Mar 31, 2016	0	-	-
Mar 31, 2015	0	-	-
Mar 31, 2014	0	-	-
Mar 31, 2013	200.40K	-1.14M	-85.07%
Mar 31, 2012	1.34M	-728.80K	-35.19%
Mar 31, 2011	2.07M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.